A novel labelling method for measuring the deposition of drug particles in the respiratory tract

Vidgrén, M.; Kärkkäinen, Anna‐Mari; Karjalainen, Panu; Paronen, T.P.

doi:10.1016/0378-5173(87)90035-4

Cited by 31 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The formulation of radiolabelled ipratropium bromide (Spiro et al 1984), sodium cromoglycate (Vidgren et al 1987a), fenoterol (Kohler et al 1988), salbutamol (albuterol) [Kohler et al 1988;Melchor et al 1993] or Teflon® (Newman et al 1981a) into clinically available inhalers has enabled 'V-scintigraphy to measure the amount of inhaled drug deposited into the lungs. Teflon® has been used in place of bronchodilators because it is easy to radiolabel, it is not absorbed, and it is cleared easily from the lungs by mucociliary action.…”

Section: Lung Deposition Studiesmentioning

confidence: 99%

Standards for Bioequivalence of Inhaled Products

Chrystyn

1994

Clinical Pharmacokinetics

View full text Add to dashboard Cite

Section: Lung Deposition Studiesmentioning

confidence: 99%

Standards for Bioequivalence of Inhaled Products

Chrystyn

1994

Clinical Pharmacokinetics

View full text Add to dashboard Cite

“…Technetium-99m is generally used as a tracer in studies of drug delivery from pressurised MDIs and powder inhalers; this radionuclide has been used to label inert solid particles (Newman et al ~981a) or liquid droplets (Dolovich et al 1981) in placebo-pressurised MDIs and has been incorporated by physical inclusion into spray-dried sodium cromoglycate particles (Vidgren et al 1987). More recently, this radionuclide has been mixed in a suitable chemical form with drug material in such a way that it acts as a valid marker for the presence of drug across a range of droplet sizes (K6hler et al 1988;Newman et al 1989aNewman et al , b, 1991.…”

Section: Drug Delivery To the Lungsmentioning

confidence: 99%

Gamma scintigraphy in the evaluation of pharmaceutical dosage forms

Davis¹,

Hardy²,

Newman³

et al. 1992

Eur J Nucl Med

122

View full text Add to dashboard Cite

Gamma-scintigraphy is applied extensively in the development and evaluation of pharmaceutical drug delivery systems. It is used particularly for monitoring formulations in the gastrointestinal and respiratory tracts. The radiolabelling is generally achieved by the incorporation of an appropriate technetium-99m or indium-111 labelled radiopharmaceutical into the formulation. In the case of complex dosage forms, such as enteric-coated tablets, labelling is best undertaken by the addition of a non-radioactive tracer such as samarium-152 oxide or erbium-170 oxide followed by neutron activation of the final product. Systems investigated include tablets and multiparticulates for oral administration, enemas and suppositories, metered dose inhalers and nebulisers, and nasal sprays and drops. Gamma-scintigraphy provides information on the deposition, dispersion and movement of the formulation. The combination of such studies with the assay of drug levels in blood or urine specimens, pharmacoscintigraphy, provides information concerning the sites of drug release and absorption. Data acquired from the scintigraphic evaluation of pharmaceutical dosage forms are now being used increasingly at all stages of product development, from the assessment of prototype delivery systems to supporting the product licence application.

show abstract